Precision diagnostics for antibiotic resistance
Reducing cost and lives lost to resistant infections
Precision diagnostics for antibiotic resistance
Reducing cost and lives lost to resistant infections
Reducing cost and lives lost to resistant infections
Reducing cost and lives lost to resistant infections
Antibiotic resistance is predicted to be the global leading cause of death by 2050, taking 10 million lives annually. New solutions are direly needed now. At Informuta, we believe in conserving our current market-approved antibiotics and learning how to better use them to improve treatment outcomes. To do this, we are leveraging machine learning and genomics data to develop RESISENSE, our breakthrough, patent-pending diagnostic that can directly tell clinicians the best drugs to use on a patient-by-patient basis.
We focus on giving hospitals and clinicians the most information on infections to aid in clinical decision-making, with the goal of enabling targeted treatment and precision-based care. Our technology allow us to be the most comprehensive and robust diagnostic for drug-resistant infections than any other on the market. We are also the first ever that can predict drug resistance in patients before it even happens, helping to improve outcomes, decrease incidence, and decrease cost of resistant infections.
We have already established proof of concept and clinically validated our algorithms on patient isolates. Our first multicenter clinical trial is set to begin September 2024, with the anticipated launch of our services in early 2025. If you are interested in participating as a clinical trial site, please contact us for more information.
Sign up to stay informed on our progress.
Our proprietary machine learning models analyze mutations, or 'errors' present in the infecting bacterial DNA. We look for global 'fingerprints' of these mutations. From these, we are able to infer the drug resistance profile of an infection. The power of this analysis is that it is completely species-independent and resistance mechanism-independent, meaning it is very easily translatable from infection-to-infection and can detect even never-before-seen resistance.
Informuta is the first to be able to detect resistance-prone infections, which are special infections that our research has shown to rapidly acquire multidrug resistance when treatment is attempted. These infections require a highly targeted, personalized medicine approach, which Informuta's platform will guide clinicians in designing for effective treatment.
Kalen is a PhD graduate from Tulane University's Biomedical Sciences PhD program, where she studied how bacteria genetically acquire multidrug resistance. Kalen has spent 4 years of research inventing Informuta's core technology.
Leo is a PhD graduate from Tulane University's Bioinnovation Program and has expertise in mechanisms of DNA damage & repair, machine learning applications, and software engineering. He spent 6 years of his research inventing Informuta's core technology.
Informuta
Copyright © 2024 Informuta - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.